786 results on '"Wechalekar, Ashutosh"'
Search Results
2. Abstract 4144740: Characteristics and Natural History of Early ATTR Cardiac Amyloid Infiltration
3. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort
4. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
5. Extensive cardiac FDG uptake in a patient with AL amyloidosis
6. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
7. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort
8. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
9. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
10. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
11. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
12. Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure
13. Abstract 11740: Redefining Cardiac Involvement in Systemic Immunoglobulin Light Chain Amyloidosis and Treatment Implications
14. Abstract 11617: Characterisation of Blood Biomarkers in Cardiac ATTR Amyloidosis
15. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
16. Daratumumab in AL amyloidosis
17. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
18. AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review
19. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
20. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
21. A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
22. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study
23. Search for AL amyloidosis risk factors using Mendelian randomization
24. High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
25. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
26. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types
27. Abstract 10063: Changes in Clinical Phenotype of Patients With ATTR Cardiac Amyloidosis During the Past 20 Years
28. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis.
29. Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab.
30. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime.
31. Wild-type transthyretin cardiac amyloidosis: When is a rare disease no longer a rare disease?
32. Systemic Amyloidosis due to Low-Grade Lymphoma
33. Standardized reporting of monoclonal immunoglobulin–associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group
34. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
35. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis
36. Refining prognostication in systemic AL amyloidosis: limited value of dFLC.
37. Systemic amyloidosis: moving into the spotlight
38. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance
39. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
40. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles
41. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
42. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3
43. Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement.
44. Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis.
45. Recommendations for good clinical practice for DPD bone scintigraphy for cardiac amyloidosis.
46. Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis.
47. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
48. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
49. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome
50. Prognosis, characterisation and treatment of systemic AL amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.